Financial Counselors Inc. decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,080 shares of the medical instruments supplier’s stock after selling 225 shares during the period. Financial Counselors Inc.’s holdings in Becton, Dickinson and were worth $601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Guardian Life Insurance Co. of America lifted its position in shares of Becton, Dickinson and by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 6 shares in the last quarter. Family Firm Inc. lifted its position in shares of Becton, Dickinson and by 0.5% during the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 6 shares in the last quarter. Northwest Quadrant Wealth Management LLC lifted its position in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 6 shares in the last quarter. Wellington Shields & Co. LLC lifted its position in shares of Becton, Dickinson and by 0.3% during the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after buying an additional 7 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in shares of Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Hedge funds and other institutional investors own 87.12% of the company’s stock.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock worth $15,242,688 over the last 90 days. Company insiders own 1.40% of the company’s stock.

Several research analysts recently commented on the company. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $200.93.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 198.08 on Friday. The firm has a market capitalization of $45.08 billion, a P/E ratio of 57.36 and a beta of 1.05. The firm has a 50 day moving average price of $197.22 and a 200-day moving average price of $192.46. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the business earned $2.35 earnings per share. The business’s revenue was down 5.1% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were given a $0.73 dividend. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/08/becton-dickinson-and-company-bdx-stake-lessened-by-financial-counselors-inc.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.